Harrow, Inc. Repayment of Notes Receivable from Related Parties
Harrow, Inc. (HROW) reported Repayment of Notes Receivable from Related Parties of $4.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-13.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RepaymentOfNotesReceivableFromRelatedParties · last filed 2020-03-13
- Harrow, Inc. repayment of notes receivable from related parties for the quarter ending 2018-12-31 was $0.00.
- Harrow, Inc. repayment of notes receivable from related parties for the quarter ending 2018-09-30 was $0.00.
- Harrow, Inc. repayment of notes receivable from related parties for the quarter ending 2018-06-30 was $0.00.
- Harrow, Inc. repayment of notes receivable from related parties for the quarter ending 2018-03-31 was $4.00K.
- Harrow, Inc. repayment of notes receivable from related parties for fiscal 2018 was $4.00K.
| Period end | Repayment of Notes Receivable from Related Parties 3 month | Repayment of Notes Receivable from Related Parties 6 month | Repayment of Notes Receivable from Related Parties 9 month | Repayment of Notes Receivable from Related Parties 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $0.00 derived: sum of 2 quarters · filed 2020-03-13 | $0.00 derived: sum of 3 quarters · filed 2020-03-13 | $4.00K 10-K · filed 2020-03-13 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $0.00 derived: sum of 2 quarters · filed 2019-11-13 | $4.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $4.00K 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $4.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |